Tanaka T, Yoshizawa A, Tanae A, Hibi I, Shizume K
Endocrine Research Laboratory, National Children's Medical Research Center, Tokyo, Japan.
Horm Res. 1990;33 Suppl 4:102-5. doi: 10.1159/000181593.
125 boys with idiopathic GH deficiency who received GH treatment were followed until they reached their final height. In 85 patients who had spontaneous puberty (group I), the mean final height was 151.5 +/- 6.6 cm. In 23 patients with combined GH and gonadotropin deficiency (group II) whose pubertal development was induced artificially at age 19.4 +/- 2.1 years, the mean final height was 163.7 +/- 3.9 cm (p less than 0.01 vs. group I). Final height was strongly related to height at the onset of pubertal development in combined groups I and II when the time of gonadal replacement treatment was taken as the onset of pubertal development in group II. In 17 patients (group III) who developed spontaneous puberty, gonadal suppression treatment was started at their early stage of puberty and was continued for a mean duration of 4.3 +/- 1.1 years. The mean final height in group III was 157.9 +/- 3.0 cm (p less than 0.01 vs. group I, group II). Longitudinal growth pattern analysis demonstrated that this beneficial effect on final height by gonadal suppression treatment was attributed to the elongation of pubertal growth spurt and pubertal height gain.
对125名接受生长激素（GH）治疗的特发性GH缺乏症男孩进行随访，直至他们达到最终身高。在85名自然青春期发育的患者（第一组）中，平均最终身高为151.5±6.6厘米。在23名生长激素和促性腺激素联合缺乏的患者（第二组）中，其青春期发育在19.4±2.1岁时人为诱导，平均最终身高为163.7±3.9厘米（与第一组相比，P<0.01）。当将性腺替代治疗时间作为第二组青春期发育起始时间时，第一组和第二组联合分析显示最终身高与青春期发育起始时的身高密切相关。在17名自然青春期发育的患者（第三组）中，在青春期早期开始性腺抑制治疗，并持续平均4.3±1.1年。第三组的平均最终身高为157.9±3.0厘米（与第一组、第二组相比，P<0.01）。纵向生长模式分析表明，性腺抑制治疗对最终身高的这种有益作用归因于青春期生长突增期的延长和青春期身高增长。
